The German-Federal Institute for Drugs and Medical Devices (BfArM) has granted Moberg Derma approval to begin a Phase I trial for Limtop, a formulation of an immunomodulatory compound with potential to treat actinic keratosis, genital warts and basal cell carcinoma. The objective is a product with short treatment duration, an improved safety profile and an efficacy similar to or better than that of competing preparations.
Limtop is based on a patent-pending formulation of a compound that results in an optimal dose of the active substance being delivered into the skin. Preclinical results show that Limtop has a significantly better capacity than existing preparations to transport the active substance to the target tissue in the skin. Actinic keratosis is sun damage to the skin that is characterised by thickening of the horny layer of the epidermis. The condition has become more common as a result of changed lifestyle and increased exposure to strong sunlight.